The presence of amyloid co-pathology may contribute to the significant increases in inflammation detected with 11C-PK11195 PET in the cortical regions we found, which have shown early increases in amyloid pathology in DLB and Alzheimer’s disease.59,60 As such, the present results do not preclude that tau (and other protein) pathology contributes to the disease process but rather suggest that that inflammatory changes may be one of the most relevant early modifiable treatment targets in PD and other disorders. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.